普利制药(300630) - 2022 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2022 was CNY 367,925,505.63, representing a 34.58% increase compared to CNY 273,392,371.83 in the same period last year[4] - The net profit attributable to shareholders for Q1 2022 was CNY 161,777,968.14, up 33.44% from CNY 121,239,486.28 year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 148,627,173.03, reflecting a 25.53% increase from CNY 118,400,289.91 in the previous year[4] - The basic earnings per share for Q1 2022 was CNY 0.37, which is a 54.17% increase from CNY 0.24 in the previous year[4] - Total operating revenue for the current period reached ¥367,925,505.63, a significant increase of 34.7% compared to ¥273,392,371.83 in the previous period[28] - Operating profit for the current period was ¥167,770,281.15, up 35.8% from ¥123,477,888.03 in the previous period[31] - Net profit attributable to the parent company was ¥161,777,968.14, representing a 33.5% increase from ¥121,239,486.28 in the previous period[34] - Basic and diluted earnings per share increased to ¥0.37 from ¥0.24, reflecting a growth of 54.2%[34] Cash Flow - The net cash flow from operating activities for Q1 2022 was CNY 22,275,788.10, a significant increase of 97.14% compared to CNY 11,299,484.87 in the same period last year[4] - The net cash flow from operating activities was $22,275,788.10, an increase from $11,299,484.87 in the previous period, reflecting a growth of approximately 97.5%[38] - Total cash outflow from operating activities amounted to $335,379,669.36, compared to $259,947,570.35 previously, indicating a rise of about 29%[38] - The net cash flow from investing activities was -$215,463,507.52, an improvement from -$269,422,298.57, showing a reduction in losses by approximately 20%[38] - Cash inflow from financing activities totaled $448,281,111.11, down from $890,330,850.00, representing a decrease of about 49.6%[38] - The net cash flow from financing activities was $224,921,521.49, compared to $759,214,164.72 previously, indicating a decline of approximately 70.4%[38] - The ending balance of cash and cash equivalents was $470,600,079.22, a decrease from $856,254,087.18, reflecting a drop of about 45%[38] - The company reported a cash increase of $31,733,802.07 during the period, compared to an increase of $500,767,809.78 in the previous period[38] Assets and Liabilities - Total assets at the end of Q1 2022 amounted to CNY 4,939,389,761.87, marking a 5.94% increase from CNY 4,662,239,616.98 at the end of the previous year[4] - The total liabilities of the company as of March 31, 2022, were CNY 2,229,657,524.37, up from CNY 2,120,484,168.47, marking an increase of about 5.1%[24] - The company's equity attributable to shareholders at the end of Q1 2022 was CNY 2,709,732,237.50, up 6.61% from CNY 2,541,755,448.51 at the end of the previous year[4] - The company's equity attributable to shareholders rose to CNY 2,709,732,237.50 from CNY 2,541,755,448.51, reflecting an increase of approximately 6.6%[27] - The non-current assets totaled CNY 2,978,498,774.80, up from CNY 2,637,208,856.20, indicating a growth of about 12.9%[21] - Short-term borrowings increased by 34.27% to CNY 466,069,697.24 from CNY 347,114,881.92 in the previous year[8] - Short-term borrowings increased to CNY 466,069,697.24 from CNY 347,114,881.92, representing a rise of approximately 34.3%[21] - The company's contract liabilities increased to CNY 46,588,790.55 from CNY 40,639,330.34, showing a growth of about 14.3%[24] - The total current liabilities were CNY 1,039,435,709.09, slightly down from CNY 1,039,683,193.63, indicating a marginal decrease of about 0.02%[24] Expenses - Research and development expenses increased to ¥56,659,055.19, a rise of 12.9% compared to ¥50,208,146.21 in the previous period[31] - Sales expenses rose to ¥47,706,957.68, an increase of 22.6% from ¥38,904,005.07 in the previous period[31] - Total operating costs for the current period were ¥212,061,775.12, up 38.3% from ¥153,207,132.77 in the previous period[28] - Income tax expenses increased to ¥6,010,278.61 from ¥2,253,300.85, reflecting a rise of 166.5%[31] Other Income and Subsidies - Government subsidies recognized in Q1 2022 amounted to CNY 13,015,588.30, contributing to the increase in other income by 295.29% compared to CNY 3,292,648.97 in the previous year[8] - The company reported other income of ¥13,015,588.30, significantly higher than ¥3,292,648.97 in the previous period[31] Financial Reporting - The report for the first quarter was not audited, which may impact the reliability of the financial data presented[39]